SCYNEXIS Inc.'s (SCYX) Phase 1 single ascending dose and multiple ascending dose trial of intravenous SCY-247 has dosed the first participants.
SCY-247, a second-generation triterpenoid antifungal, is being developed as a treatment for invasive candidiasis (IC) and as a prophylaxis therapy for invasive fungal disease. The company expects to report results from the intravenous SCY-247trial this year.
Commenting on the development, David Angulo, President and Chief Executive Officer of SCYNEXIS, said, "An IV formulation of SCY-247 would provide additional flexibility for the optimal management of patients with invasive candidiasis and we are excited by the achievement of this important development milestone, which moves this innovative antifungal closer towards meeting the needs of patients suffering from difficult to treat severe fungal diseases."
In its oral formulation, SCY-247 showed promising results in a phase 1 single and multiple ascending dose study, demonstrating that oral administration can reach target efficacy exposures while maintaining good tolerability for the treatment and prevention of invasive fungal infections. The positive findings were reported in September 2025.
SCY-247 was granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA in January of this year.
SCYX is currently trading at $0.71, up 0.37%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.